Systematic reviews of preclinical animal studies can make significant contributions to health care and more transparent translational medicine

Merel Ritskes-Hoitinga, Marlies Leenaars, Marc Avey, Maroeska Rovers, Rob Scholten

Cochrane Database of Systematic Reviews 2014;(3):ED000078  https://doi.org/10.1002/14651858.ED000078

Preclinical evidence, like clinical evidence, is used to inform decisions about the safety and efficacy of treatments for participants in clinical trials. Unlike clinical studies, most preclinical animal studies are not systematically reviewed, even though systematic reviews of preclinical animal studies can contribute significantly to creating more transparency regarding the possible translation from preclinical animal studies to clinical trials. The expected benefits of systematic reviews of preclinical animal studies encompass stimulating better science and improving translation. Fewer than 250 systematic reviews of preclinical animal studies were published prior to 2010, whereas almost 6000 Cochrane Reviews have been published to date.

The quality of methodology and reporting of preclinical animal studies is currently inadequate and the use of quality and risk of bias assessments in systematic reviews has contributed to the exposure of this problem. Few preclinical animal studies report the use of randomisation, allocation concealment, blinding of personnel, or blind assessments of outcomes. To improve reporting for preclinical animal studies, guidelines have been developed and are being implemented by journals and publishers. Another problem is that negative results are often not published, leading to publication bias, blurring the interpretation and validity of the research findings. Even though the current situation identifies serious shortcomings in primary studies, there are examples that demonstrate the value of systematic reviews. One unique challenge with animal studies is the large amount of heterogeneity between studies. Systematic reviews and meta-analysis help to make heterogeneity transparent, creating clues for causative factors and possible mechanisms, and new hypotheses, and practical methods already exist for exploring this heterogeneity within meta-analysis of preclinical systematic reviews.

Systematic reviews and meta-analyses of preclinical animal studies create an overview of what has been published and how, including judgements on possible translation. Based on systematic reviews of preclinical animal studies, Horn and colleagues found no evidence to justify the start of clinical trials of nimodipine for focal cerebral ischaemia in humans. However, this review was conducted after 7665 patients participated in clinical trials and a Cochrane Review with the same conclusion was published a year earlier. Similarly, Pound and colleagues demonstrated that drug side effects (excess risk of intracranial hemorrhage after thrombolysis treatment for acute stroke) found during the clinical trial could have been identified beforehand if a systematic review of preclinical animal studies had been performed. There are also examples showing that reliance on narrative reviews of preclinical animal studies to justify the start of clinical trials in humans can be misplaced. Therefore, systematic reviews of preclinical animal studies carried out prior to the start of clinical trials can save resources and can lead to improved safety for participants in clinical trials, and ultimately better health care.

For all these reasons, a small but growing international community of researchers is conducting systematic reviews of preclinical animal studies. The Collaborative Approach to Meta Analysis and Review of Animal Data from Experimental Studies (CAMARADES; www.camarades.info) and the Systematic Review Centre for Laboratory animal Experimentation (SYRCLE; www.SYRCLE.nl) are at the forefront. CAMARADES is routinely performing systematic reviews of preclinical animal studies in stroke and other neurological disorders and has formed a worldwide network. SYRCLE has focussed on the development of methodology and guidelines and offers teaching and training internationally, in addition to performing collaborative systematic reviews. SYRCLE took the initiative for the first international symposium on systematic reviews in laboratory animal science (Nijmegen, 2012), and the second international symposium was organised by CAMARADES in cooperation with SYRCLE (Edinburgh, 2013). The conclusion from these meetings is that more systematic reviews of preclinical animal studies are urgently needed. Moreover, much more effort is needed in the field of education, and good reporting and conduct of systematic reviews, in order to achieve more high-quality systematic reviews.

For conducting preclinical systematic reviews, Cochrane
methodology was the starting point and it has been transformed to be specifically for preclinical animal studies. A number of tools have been developed such as the search guide,[19] search filters,[20][21][22] meta-analysis methods,[16] reporting guidelines for preclinical systematic reviews,[23] and risk of bias assessment.[24] Although good progress has been made, methods and tools still need to be developed and improved upon for the conduct of systematic reviews in preclinical animal studies. In addition, much more education, teaching, and training is necessary because animal researchers have little or no training in systematic review methodology. For further development of tools, methods, education and guidelines an animal methods group would be the way forward.

During the Cochrane Colloquium in Quebec City, Canada (September 2013), SYRCLE organised a workshop and special meeting, with the aim to discuss the value of systematic reviews of preclinical animal studies and their potential relevance to Cochrane. There was overall endorsement for starting an official methods group on systematic reviews of preclinical animal studies in an international collaborative network. The proposed methods group would focus on developing methods for the systematic review of preclinical animal studies, improving the quality of primary preclinical animal studies, and improving the translation from preclinical and clinical trials.

With the establishment of a preclinical animal study methods group in close co-operation with Cochrane, we hope to further advocate the need for and promote the preparation of systematic reviews of preclinical animal studies to aid making better well-informed decisions about health care. Anyone interested in this methods group may contact the first author.

Author information
Merel Ritskes-Hoitinga1, Marlies Leenaars1, Marc Avey2, Maroeska Rovers3, Rob Scholten4
1 SYRCLE, Radboud University Medical Center, Nijmegen, the Netherlands.
2 Ottawa Hospital Research Institute, Canada.
3 Department for Health Evidence, Radboud University Medical Center, Nijmegen, the Netherlands.
4 Dutch Cochrane Centre, University Medical Center Utrecht, the Netherlands.

Declarations of interest
The authors have completed the Unified Competing Interest form at www.icmje.org/coiDisclosure.pdf (available upon request).

References
6. van der Worp HB, Sandercock PAG. Improving the process of translational research. BMJ 2012;345:e7837. http://dx.doi.org/10.1136/bmj.e7837
12. Hooijmans CR, Leenaars M, Ritskes-Hoitinga M. A gold standard publication checklist to improve the quality of animal studies, to fully integrate the three Rs, and to make systematic reviews more feasible. Alternatives to Laboratory Animals 2010;38(2):167-82.

Systematic reviews of preclinical animal studies can make significant contributions to health care and more transparent translational medicine (Editorial)
Copyright © 2014 The Cochrane Collaboration | Published by John Wiley & Sons, Ltd. | https://doi.org/10.1002/14651858.ED000078
www.cochranelibrary.com

14. Sena ES, van der Worp HB, Bath PM, Howells DM, Macleod MR. Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. *PLOS Biology* 2010;8(3):e1000344. doi.org/10.1371/journal.pbio.1000344


Systematic reviews of preclinical animal studies can make significant contributions to health care and more transparent translational medicine (Editorial)